Oncternal Therapeutics (NASDAQ:ONCT) PT Lowered to $28.00

Oncternal Therapeutics (NASDAQ:ONCT) had its price target trimmed by HC Wainwright from $30.00 to $28.00 in a report published on Monday, Benzinga reports. The firm currently has a buy rating on the stock. HC Wainwright also issued estimates for Oncternal Therapeutics’ Q1 2024 earnings at ($3.30) EPS, Q2 2024 earnings at ($3.42) EPS, Q3 2024 earnings at ($3.63) EPS, Q4 2024 earnings at ($3.68) EPS and FY2024 earnings at ($14.04) EPS.

Separately, StockNews.com upgraded shares of Oncternal Therapeutics from a sell rating to a hold rating in a report on Friday, March 8th.

Oncternal Therapeutics Trading Down 3.9 %

Shares of NASDAQ ONCT opened at $8.60 on Monday. The stock has a market capitalization of $23.13 million, a PE ratio of -0.64 and a beta of 1.26. Oncternal Therapeutics has a twelve month low of $5.57 and a twelve month high of $13.14. The stock has a fifty day simple moving average of $8.90 and a 200-day simple moving average of $8.11.

Oncternal Therapeutics (NASDAQ:ONCT) last released its earnings results on Thursday, March 7th. The company reported ($3.11) earnings per share for the quarter, missing the consensus estimate of ($3.09) by ($0.02). The firm had revenue of $0.30 million during the quarter, compared to analyst estimates of $0.17 million. Oncternal Therapeutics had a negative net margin of 5,029.17% and a negative return on equity of 95.87%. During the same period in the prior year, the firm earned ($4.00) earnings per share. On average, equities analysts predict that Oncternal Therapeutics will post -12.03 earnings per share for the current year.

Insider Activity at Oncternal Therapeutics

In related news, Director Robert James Wills purchased 3,086 shares of the business’s stock in a transaction on Monday, April 8th. The shares were bought at an average price of $8.96 per share, for a total transaction of $27,650.56. Following the acquisition, the director now directly owns 10,000 shares in the company, valued at $89,600. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last three months, insiders purchased 10,714 shares of company stock worth $92,736. Company insiders own 8.00% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Citadel Advisors LLC purchased a new stake in shares of Oncternal Therapeutics in the 4th quarter valued at approximately $29,000. Prudential Financial Inc. acquired a new position in shares of Oncternal Therapeutics during the second quarter worth $32,000. Mirabella Financial Services LLP acquired a new position in shares of Oncternal Therapeutics during the first quarter worth $38,000. Virtu Financial LLC purchased a new position in Oncternal Therapeutics in the second quarter valued at $48,000. Finally, Pasadena Private Wealth LLC acquired a new stake in Oncternal Therapeutics in the third quarter valued at $84,000. Hedge funds and other institutional investors own 16.05% of the company’s stock.

Oncternal Therapeutics Company Profile

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.